| Migraine Disorders
Nurtec ODT vs Reyvow
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Nurtec Odt vs Reyvow with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsReyvow has a higher rate of injection site reactions vs Nurtec Odt based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Reyvow but not Nurtec Odt, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nurtec Odt
Reyvow
At A Glance
Oral
As needed or every other day
CGRP receptor antagonist
Oral
As needed
5-HT1F receptor agonist
Indications
- Migraine Disorders
- Episodic migraine
- Migraine Disorders
Dosing
Migraine Disorders 75 mg orally as needed; maximum 75 mg per 24-hour period; safety of more than 18 doses in a 30-day period has not been established; may be taken with or without food.
Episodic migraine 75 mg orally every other day, with or without food.
Migraine Disorders 50 mg, 100 mg, or 200 mg orally as needed; no more than one dose in 24 hours; wait at least 8 hours between dosing and driving or operating machinery; swallow tablets whole.
Contraindications
- History of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components, including anaphylaxis and delayed serious hypersensitivity
—
Adverse Reactions
Most common Nausea, abdominal pain/dyspepsia
Serious Hypersensitivity including dyspnea and severe rash
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Most common (>=2%) dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, muscle weakness
Serious hypersensitivity reactions including angioedema, rash, and photosensitivity reaction
Pharmacology
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it is an orally administered small molecule that blocks the CGRP receptor implicated in migraine pathophysiology, indicated for both acute and preventive treatment.
5-HT1F receptor agonist; lasmiditan binds with high affinity to the 5-HT1F receptor and presumably exerts its therapeutic effects in migraine through agonist activity at this receptor, though the precise mechanism is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nurtec Odt
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (12/12)
Reyvow
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Nurtec Odt
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Reyvow
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (4/8)
Humana
Nurtec Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Reyvow
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Reyvow.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Nurtec OdtView full Nurtec Odt profile
ReyvowView full Reyvow profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.